|
Male, n (%)
|
80 (64.0)
|
13 (81.3)
|
|
Age (years), median (range)
|
51.0 (22–72)
|
52.5 (33–65)
|
|
BMI (kg/m2), median (range)
|
27.4 (18.9–45.8)
|
27.1 (20.4–35.3)
|
|
Race, n (%)
|
|
White
|
121 (96.8)
|
14 (87.5)
|
|
Black/African American
|
3 (2.4)
|
1 (6.3)
|
|
American Indian/Alaskan native
|
0
|
1 (6.3)
|
|
Native Hawaiian or other Pacific Islander
|
1 (0.8)
|
0
|
|
Ethnicity, n (%)
|
|
Hispanic or Latino
|
7 (5.6)
|
1 (6.3)
|
|
Not Hispanic or Latino
|
118 (94.4)
|
15 (93.8)
|
|
Time since diagnosis (years), median (range)
|
7.1 (2.1–35.4)
|
6.1 (0.7–20.4)
|
|
SMV therapy-experienced, yes, n (%)
|
125 (100)
|
8 (50)
|
|
PegIFN/RBV therapy-experienced, yes, n (%)
|
125 (100)
|
9 (56.2)
|
|
Response to last course of PegIFN/RBV therapy, n (%)
|
|
Viral relapser
|
55 (44.0)
|
–
|
|
Viral breakthrough
|
10 (8.0)
|
–
|
|
Non-responder
|
60 (48.0)
|
–
|
|
Partial responder
|
28 (22.4)
|
–
|
|
Null responder
|
30 (24.0)
|
–
|
|
Other (non-classifiable non-responder)
|
2 (1.6)
|
–
|
|
Baseline HCV RNA (log10 IU/ml), median (range)
|
6.53 (4.9–7.8)
|
6.68 (5.6–7.2)
|
|
IL28B genotype, n (%)
|
|
CC
|
20 (16.0)
|
1 (6.3)
|
|
CT
|
87 (69.6)
|
9 (56.3)
|
|
TT
|
18 (14.4)
|
6 (37.5)
|
|
HCV geno/subtype
|
|
1a
|
50 (40.0)
|
14 (87.5)
|
|
1a with Q80K
|
12/50 (24.0)
|
3/14 (21.4)
|
|
1a without Q80K
|
38/50 (76.0)
|
11/14 (78.6)
|
|
1b
|
75 (60.0)
|
2 (12.5)
|
|
HOMA-IR,a
n (%)
|
|
<2
|
46/120 (38.3)
|
4/14 (28.6)
|
|
≥2 to ≤4
|
43/120 (35.8)
|
7/14 (50.0)
|
|
>4
|
31/120 (25.8)
|
3/14 (21.4)
|
|
METAVIR fibrosis score, n (%)
|
|
F0, 1, or 2
|
85 (68.0)
|
13 (81.3)
|
|
F3
|
18 (14.4)
|
3 (18.8%)
|
|
F4
|
22 (17.6)
|
0
|
|
Baseline ALT WHO toxicity grade, n (%)
|
|
Grade 0
|
66 (52.8)
|
10 (62.5)
|
|
Grade 1/2
|
56 (44.8)
|
6 (37.5)
|
|
Grade 3
|
3 (2.4)
|
0
|
|
Grade 4
|
0
|
0
|
